Eli Lilly has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

A new report shows up to 7.2 million Americans aged 65 and older are living with Alzheimer’s disease, an increase of about ...

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies plan to bring into phase 2/3 trials to test in patients with early Alzheimer's disease.

Lilly has said that its drug has advantages over Leqembi ... very meaningful results for people with early symptomatic Alzheimer's disease and can now help to improve the standard of care for ...

Lilly’s neurodegeneration portfolio is anchored by the Alzheimer’s drug Kisunla, which received FDA approval last July. That antibody drug was internally discovered and developed within Lilly.

A world-leading experimental dementia drug designed to prevent the disease before it begins will be trialled in Australia for ...

Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headaches if she tried a new drug from Eisai Co. that promised to slow the ...